Plozasiran sodium is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase III program in Familial Chylomicronemia (Type I Hyperlipoproteinemia). According to Globaldata, it is involved in 11 clinical trials, of which 4 were completed, 5 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Plozasiran sodium’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
Smarter leaders trust GlobalData
The revenue for Plozasiran sodium is expected to reach an annual total of $326 mn by 2036 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Plozasiran sodium Overview
Arrowhead Pharmaceuticals Overview
Arrowhead Pharmaceuticals (Arrowhead) is a biotech company that develops and commercializes gene silencing therapeutics. The company utilizes RNA chemistries and TRiM platform to target and silence disease-causing genes. Its pipeline products include ARO-APOC3, ARO-ANG3, Olpasiran, GSK-4532990, ARO-PNPLA3, ARO-RAGE, ARO-MMP7, ARO-MUC5AC, Fazirsiran, ARO-HB, ARO-DUX4 and ARO-DM1. Arrowhead product indications include hypertriglyceridemia, dyslipidemia, cardiovascular disease, nonalcoholic steatohepatitis, inflammatory, idiopathic pulmonary fibrosis, idiopathic pulmonary fibrosis, much-obstructive, alpha-1 liver disease, hepatitis b, facioscapulohumeral muscular dystrophy and myotonic dystrophy type 1. The company operates lab facilities in San Diego, California and Madison, Wisconsin, the US. Arrowhead is headquartered in Pasadena, California, the US.
The company reported revenues of (US Dollars) US$240.7 million for the fiscal year ended September 2023 (FY2023), a decrease of 1% over FY2022. The operating loss of the company was US$205 million in FY2023, compared to an operating loss of US$178.5 million in FY2022. The net loss of the company was US$205.3 million in FY2023, compared to a net loss of US$176.1 million in FY2022.
For a complete picture of Plozasiran sodium’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
